secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xilio Therapeutics, Inc. (XLO)
CIK:        0001840233
Form:       8-K
Filed at:   2025-03-11T23:59:59+00:00
Accession:  0001193125-25-051532
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xilio Therapeutics enters into $50M ATM equity offering with Leerink Partners
-----------------------------------------------------------------------------

- Xilio entered into Sales Agreement with Leerink Partners to sell up to $50M of common stock via ATM offering.
- Agent Leerink will receive 3.0% commission on gross proceeds from any shares sold under the agreement.
- Sales will be made on Nasdaq Global Select Market under effective S-3 registration statement filed Nov 2022.
- No minimum sales obligation; company retains discretion over timing and amount of any sales.
- The ATM facility was established on March 11, 2025; either party may terminate upon written notice.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840233/000119312525051532/0001193125-25-051532-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840233/000119312525051532/d897420d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-051532

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer